Patents by Inventor Chunjun CHU

Chunjun CHU has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10918645
    Abstract: Provided are a substituted tricyclic heterocyclic compound of formula I or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt, ester or a prodrug thereof, a pharmaceutical composition including the same and uses thereof. The substituted tricyclic heterocyclic compounds and the pharmaceutical compositions comprising the compounds disclosed herein can be used for treating a disorder caused by at least one of cancer and neurodegenerative diseases. Further the compounds and the pharmaceutical compositions comprising the compounds disclosed herein can be also used for preventing or treating a disorder caused by, associated with or accompanied by any abnormal kinase activity.
    Type: Grant
    Filed: June 13, 2017
    Date of Patent: February 16, 2021
    Assignees: LIFEARC, SUZHOU YABAO PHARMACEUTICAL R&D CO., LTD.
    Inventors: Yan Xia, Edward Giles McIver, Yang Song, Yuanyuan Xu, Lin Zhu, Chunjun Chu, Ling Wu, Miao Liu, Justin Stephen Bryans
  • Publication number: 20190307763
    Abstract: Provided are a substituted tricyclic herteocyclic compound of formula I or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt, ester or a prodrug thereof, a pharmaceutical composition including the same and uses thereof. The substituted tricyclic herteocyclic compounds and the pharmaceutical compositions comprising the compounds disclosed herein can be used for treating a disorder caused by at least one of cancer and neurodegenerative diseases. Further the compounds and the pharmaceutical compositions comprising the compounds disclosed herein can be also used for preventing or treating a disorder caused by, associated with or accompanied by any abnormal kinase activity.
    Type: Application
    Filed: June 13, 2017
    Publication date: October 10, 2019
    Applicants: LifeArc, Suzhou Yabao Pharmaceutical R&D Co., Ltd.
    Inventors: Yan XIA, Edward Giles MCIVER, Yang SONG, Yuanyuan XU, Lin ZHU, Chunjun CHU, Ling WU, Miao LIU, Justin Stephen BRYANS